Quick Answer
LIGAND PHARMACEUTICALS INC reported Total Revenue of $268.09 million for fiscal year 2025.
LIGAND PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $268.09M +60.4% |
$167.13M +27.3% |
$131.31M -33.1% |
$196.25M -18.8% |
$241.54M +47.7% |
$163.56M +36.0% |
| Revenue (ASC 606) | $268.09M +60.4% |
$167.13M +27.3% |
$131.31M -33.1% |
$196.25M -18.8% |
$241.54M +47.7% |
$163.56M +36.0% |
| Net Income | $124.45M +3186.6% |
-$4.03M -107.7% |
$52.15M +256.3% |
-$33.36M -158.4% |
$57.14M +2014.2% |
-$2.98M -100.5% |
| Diluted EPS | $6.13 +2886.4% |
-$0.22 -107.5% |
$2.94 +248.5% |
-$1.98 -159.8% |
$3.31 +1938.9% |
-$0.18 -100.6% |
| Total Assets | $1.56B +65.7% |
$941.77M +19.6% |
$787.22M +3.2% |
$762.67M -41.2% |
$1.30B -4.7% |
$1.36B -8.9% |
| Cash and Equivalents | $174.93M +141.9% |
$72.31M +215.0% |
$22.95M -49.0% |
$45.01M +130.5% |
$19.52M -59.0% |
$47.62M -33.4% |
| Stockholders Equity | $1.02B +22.5% |
$830.44M +18.5% |
$700.91M +17.3% |
$597.49M -27.2% |
$821.16M +15.7% |
$709.52M -7.5% |
| R&D Expense | $81.18M +278.9% |
$21.43M -12.7% |
$24.54M -32.0% |
$36.08M +12.4% |
$32.10M -20.7% |
$40.50M -27.6% |
| Operating Income | $41.00M +281.4% |
-$22.61M -289.3% |
$11.94M +293.2% |
$3.04M -97.1% |
$103.85M +176.9% |
$37.50M -95.4% |
| Shares Outstanding | 19.77M +3.5% |
19.11M +8.8% |
17.56M +3.6% |
16.95M +1.1% |
16.77M +4.3% |
16.08M -4.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $115.46M | +122.8% | +142.4% |
| Revenue (ASC 606) | September 30, 2025 | $115.46M | +122.8% | +142.4% |
| Net Income | September 30, 2025 | $117.27M | +1735.2% | +2319.5% |
| Diluted EPS | September 30, 2025 | $5.68 | +1556.4% | +2266.7% |
| Total Assets | September 30, 2025 | $1.48B | +54.7% | +55.7% |
| Cash and Equivalents | September 30, 2025 | $139.38M | +119.1% | +106.0% |
| Stockholders Equity | September 30, 2025 | $950.17M | +13.0% | +14.9% |
| R&D Expense | September 30, 2025 | $21.02M | +270.4% | +220.1% |
| Operating Income | September 30, 2025 | $54.93M | +1647.7% | +550.5% |
| Shares Outstanding | September 30, 2025 | 19.66M | +4.8% | +1.3% |
- LIGAND PHARMACEUTICALS INC reported Total Revenue of $268.09 million for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +60.4% in Total Revenue compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Revenue (ASC 606) of $268.09 million for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +60.4% in Revenue (ASC 606) compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Net Income of $124.45 million for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +3186.6% in Net Income compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Diluted EPS of $6.13 per share for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +2886.4% in Diluted EPS compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Total Assets of $1.56 billion for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +65.7% in Total Assets compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Cash and Equivalents of $174.93 million for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +141.9% in Cash and Equivalents compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Stockholders Equity of $1.02 billion for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +22.5% in Stockholders Equity compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported R&D Expense of $81.18 million for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +278.9% in R&D Expense compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Operating Income of $41.00 million for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +281.4% in Operating Income compared to the prior fiscal year.
- LIGAND PHARMACEUTICALS INC reported Shares Outstanding of 19.77 million shares for fiscal year 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +3.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: